In 2020, the HIV Prevention Trials Network announced results from Give PrEP a shot , a global randomized study that compares the effectiveness of injections and oral tablets as pre exposure prophylaxis (PrEP) to prevent HIV The study examines whether an experimental treatment based on the injection every 8 weeks of the anti HIV drug cabotegravir can safely protect people from getting HIV infection at least as well a standard of care treatment based on a daily oral tablet of another anti HIV medication commonly known as Truvada Overall, the study included 4,494 eligible participants, with two thirds of the participants being under 30 years of age The table below reports the number of HIV infections among the study participants for each treatment Compute the standard error for the sam ple proportion of the population that is under 30 years of age The Food and Drug Administration is seeking your input re garding the approval of the experimental treatment (cabotegravir) as anti HIV medication Based on the available data, what would you recommend to the FDA Why Give PrEP a shot In 2020, the HIV Prevention Trials Network announced results from Give PrEP a shot, a global randomized study that compares the effectiveness of injections and oral tablets as preexposure prophylaxis (PrEP) to prevent HIV The study examines whether an experimental treatment based on the injection every 8 weeks of the antiHIV drug cabotegravir can safely protect people from getting HIV infection at least as well a standard ofcare treatment based on a daily oral tablet of another antiHIV medication commonly known as Truvada Overall, the study included 4,494 eligible participants, with two thirds of the participants being under 30 years of age The table below reports the number of HIV infections among the study participants for each treatment (The table is also included in the worksheet PrEP ) Standard OfCare Experimental Treatment Treatment Tot a (Truvada) (cab otegravir) HIV infections 52 39 13 Participants 4,494 2,250 2,244

The Answer is in the image, click to view ...

Answered step by step

Verified Expert Solution

Link Copied!

Question

1 Approved Answer

Posted on Jun 23, 2024

In 2020, the HIV Prevention Trials Network announced results from Give PrEP a shot , a global randomized study that compares the effectiveness of injections

In 2020, the HIV Prevention Trials Network announced results from Give PrEP a shot, a global randomized study that compares the effectiveness of injections and oral tablets as pre-exposure prophylaxis (PrEP) to prevent HIV. The study examines whether an experimental treatment based on the injection every 8 weeks of the anti-HIV drug cabotegravir can safely protect people from getting HIV infection at least as well a standard-of-care treatment based on a daily oral tablet of another anti-HIV medication commonly known as Truvada.

Overall, the study included 4,494 eligible participants, with two-thirds of the participants being under 30 years of age. The table below reports the number of HIV infections among the study participants for each treatment.

Compute the standard error for the sam- ple proportion of the population that is under 30 years of age.

The Food and Drug Administration is seeking your input re- garding the approval of the experimental treatment (cabotegravir) as anti-HIV medication. Based on the available data, what would you recommend to the FDA? Why?

Give PrEP a shot In 2020, the HIV Prevention Trials Network announced results from Give PrEP a shot, a global randomized study that compares the effectiveness of injections and oral tablets as preexposure prophylaxis (PrEP) to prevent HIV. The study examines whether an experimental treatment based on the injection every 8 weeks of the antiHIV drug cabotegravir can safely protect people from getting HIV infection at least as well a standard-ofcare treatment based on a daily oral tablet of another antiHIV medication commonly known as Truvada. Overall, the study included 4,494 eligible participants, with two-thirds of the participants being under 30 years of age. The table below reports the number of HIV infections among the study participants for each treatment. (The table is also included in the worksheet PrEP.) Standard-OfCare Experimental Treatment Treatment Tot a] (Truvada) (cab otegravir) HIV infections 52 39 13 Participants 4,494 2,250 2,244